Map Home
Type / to search with text or keywords
/
keyboard shortcut: Type "/" on your keyboard for a quick search
Search button
Loading...
Loading...
Scroll left
Grants
Citations
H-Index
Patents
News
Books
Scroll right
Collapse sidebar
Data issues & feedback
Adjust height of sidebar
KMap
Grant
Adjust height of sidebar
KMap
Grant
A Phase 3 Randomized Clinical Study of MK-4280A (coformulated favezelimab (MK-4280) plus pembrolizumab (MK-3475)) Versus Physician's Choice Chemotherapy in PD-(L)1-refractory, Relapsed or Refractory C
Active
$1.3M Funding
2 People
External
Related Topics
immunotherapy,
clinical trial,
cancer treatment,
precision medicine
People
Michele Holland
(CD)
Cancer Center Division
﹒Research Compliance Administrator II
Abhijeet Kumar
Principal Investigator (PI)
Medicine
﹒Associate Professor, Medicine - (Clinical Scholar Track)
